SimplePractice vs Becton Dickinson
Side-by-side comparison of AI visibility scores, market position, and capabilities
All-in-one practice management platform for 185,000+ therapists, counselors, social workers, and wellness practitioners; Santa Monica-based;
About
SimplePractice is a Santa Monica-based practice management software company serving independent therapists, counselors, social workers, nutritionists, and other health and wellness practitioners. The platform provides scheduling, client intake forms, HIPAA-compliant telehealth video sessions, insurance billing, payment processing, progress notes, and client messaging in a unified system designed specifically for solo and small group private practices. SimplePractice handles the administrative burden of running a private practice — eligibility verification, superbills, ERA processing — enabling clinicians to spend more time with clients and less time on paperwork. The company serves over 185,000 practitioners across the United States and has become the dominant practice management platform in the mental health private practice segment. Founded in 2012, SimplePractice raised over $50M from investors including Susquehanna Growth Equity and has grown organically through referrals within the therapist community. It competes with TherapyNotes, TheraNest, and Therapy Brands in the mental health software market.
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
About
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.